In this post-hoc analysis of the SURMOUNT-1 trial, there was a mostly linear relationship between percentage change in weight ...

Reductions in pain catastrophizing are more closely associated with improvements in emotional functioning than with pain ...

1. Median overall survival was 13.6 months in the tarlatamab group and 8.3 months in the chemotherapy group, with HR 0.60 (significant) 2. Adverse events grade 3 or higher occurred in 54% of the ...

For patients with facet-mediated spine pain that achieve ≥80% pain relief after a medial branch block, a second diagnostic ...

Routine single-session screening for emotional and cognitive issues post-stroke does not improve long-term societal ...

In this microsimulation model, initiation of anal cancer screening in men who have sex with men with human immunodeficiency ...

AI-assisted electrocardiogram (ECG) improves early detection of low ejection fraction in hospitalized patients by enhancing ...

Liang and colleagues retrospectively compared Generative Pretrained Transformer 4 (GPT-4)’s comments on scientific papers to ...

Median overall survival was 3.1 months greater in the nivolumab plus ipilimumab group. 2. Grade 3-4 treatment-related adverse ...

Shoulder dystocia was less common in the early induction group compared to standard care. 2. Serious adverse events were ...

Frailty scores alone (mFI-5, CCI) are poor predictors of intensive care unit (ICU) admission or prolonged hospital stay in ...

Respiratory outcomes for preterm infants with a patent ductus arteriosus (PDA) undergoing transcatheter closure compared to ...